BR0208167A - Derivado triazaespiro[5.5]undecano e composição farmacêutica compreendendo o mesmo como um ingrediente ativo - Google Patents

Derivado triazaespiro[5.5]undecano e composição farmacêutica compreendendo o mesmo como um ingrediente ativo

Info

Publication number
BR0208167A
BR0208167A BR0208167-9A BR0208167A BR0208167A BR 0208167 A BR0208167 A BR 0208167A BR 0208167 A BR0208167 A BR 0208167A BR 0208167 A BR0208167 A BR 0208167A
Authority
BR
Brazil
Prior art keywords
formula
triazaspiro
derivative
pharmaceutical composition
active ingredient
Prior art date
Application number
BR0208167-9A
Other languages
English (en)
Inventor
Hiromu Habashita
Shin-Ichi Hamano
Shiro Shibayama
Yoshikazu Takaoka
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of BR0208167A publication Critical patent/BR0208167A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)

Abstract

"DERIVADO TRIAZAESPIRO [5.5] UNDECANO E COMPOSIçãO FARMACêUTICA COMPREENDENDO O MESMO COMO UM INGREDIENTE ATIVO". Derivados triazaespiro[5.5]undecano de fórmula (I), sais de amónio quaternário destes, N-óxidos destes, sais não-tóxicos destes ou composições farmacêuticas que os compreendem como ingredientes ativos (onde R^ 1^ é fórmula (II) ou fórmula (III), R^ 2^ é alquila ou alquinila, etc., R^ 3^, R^ 4^ é H, alquila (substituído) etc., ou R^ 3^ e R^ 4^ juntos formam fórmula (IV), R^ 5^ é H ou alquila). N.T.: copiar as fórmulas da página do Resumo Portanto, os compostos de fórmula (I) regulam o efeito de quimiocina/receptor de quimiocina, são usados para prevenção e tratamento de várias doenças inflamatórias, asma, dermatite atópica, urticária, doenças alérgicas, nefrite, nefropatia, hepatite, artrite ou artrite reumatóide, etc.
BR0208167-9A 2001-03-19 2002-03-18 Derivado triazaespiro[5.5]undecano e composição farmacêutica compreendendo o mesmo como um ingrediente ativo BR0208167A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001079610 2001-03-19
JP2001160251 2001-05-29
PCT/JP2002/002554 WO2002074770A1 (fr) 2001-03-19 2002-03-18 Derives de triazaspiro[5.5]undecane et medicaments les contenant en tant que principe actif

Publications (1)

Publication Number Publication Date
BR0208167A true BR0208167A (pt) 2004-03-09

Family

ID=26611613

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208167-9A BR0208167A (pt) 2001-03-19 2002-03-18 Derivado triazaespiro[5.5]undecano e composição farmacêutica compreendendo o mesmo como um ingrediente ativo

Country Status (23)

Country Link
US (2) US7053090B2 (pt)
EP (2) EP1619194A3 (pt)
JP (1) JP3558079B2 (pt)
KR (1) KR100714154B1 (pt)
CN (1) CN1291988C (pt)
AT (1) ATE328884T1 (pt)
AU (1) AU2002238947B2 (pt)
BR (1) BR0208167A (pt)
CA (1) CA2440264A1 (pt)
CZ (1) CZ20032531A3 (pt)
DE (1) DE60212110T2 (pt)
DK (1) DK1378510T3 (pt)
ES (1) ES2266452T3 (pt)
HU (1) HUP0400229A2 (pt)
IL (1) IL157819A0 (pt)
MX (1) MXPA03008529A (pt)
NO (1) NO20034148L (pt)
NZ (1) NZ528249A (pt)
PL (1) PL364427A1 (pt)
PT (1) PT1378510E (pt)
RU (1) RU2269528C2 (pt)
TW (1) TWI254047B (pt)
WO (1) WO2002074770A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ528270A (en) * 2001-03-19 2005-10-28 Ono Pharmaceutical Co Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
CN1688577A (zh) * 2002-09-18 2005-10-26 小野药品工业株式会社 三氮杂螺[5.5]十一烷衍生物及以它为活性成分的药物
AU2003271057A1 (en) * 2002-09-18 2004-04-08 Ono Pharmaceutical Co., Ltd. Novel crystals of triazaspiro(5.5)undecane derivative
EP1570860A4 (en) * 2002-12-13 2009-06-03 Ono Pharmaceutical Co ANTAGONIST AND AGONIST BINDING TO A STRONG BINDING SITE OF THE CHEMOKINE RECEPTOR
ATE402176T1 (de) * 2002-12-13 2008-08-15 Smithkline Beecham Corp Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
ATE405269T1 (de) * 2002-12-13 2008-09-15 Smithkline Beecham Corp Cyclohexylverbindungen als ccr5-antagonisten
CA2517888C (en) 2003-03-14 2012-05-01 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
JP4710606B2 (ja) * 2003-04-18 2011-06-29 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
EP1621540A4 (en) * 2003-04-21 2008-07-23 Ono Pharmaceutical Co HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN AND USE THEREOF
US20070270429A1 (en) * 2003-05-06 2007-11-22 Shiro Shibayama Function Inhibitor of Effector Cell
WO2006022454A1 (ja) 2004-08-27 2006-03-02 Ono Pharmaceutical Co., Ltd 塩基性基を含有する化合物およびその用途
TWI400232B (zh) 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
US8680092B2 (en) 2005-02-25 2014-03-25 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic compound and medicinal use thereof
WO2006115845A1 (en) 2005-04-20 2006-11-02 Merck & Co., Inc. Benzothiophene derivatives
CN101163690A (zh) 2005-04-20 2008-04-16 默克公司 苯并噻吩异羟肟酸衍生物
JP2008536924A (ja) 2005-04-20 2008-09-11 メルク エンド カムパニー インコーポレーテッド ベンゾチオフェンヒドロキサミン酸のカーバメート、ウレア、アミドおよびスルホンアミド置換誘導体
US20110052612A1 (en) * 2005-05-31 2011-03-03 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
AU2006262166A1 (en) 2005-06-24 2007-01-04 Merck Sharp & Dohme Corp. Modified malonate derivatives
PL1961744T3 (pl) 2005-11-18 2013-09-30 Ono Pharmaceutical Co Związek zawierający grupę zasadową oraz jego zastosowanie
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
AU2007221207A1 (en) 2006-02-28 2007-09-07 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase
CA2644368A1 (en) * 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
AU2007243519A1 (en) 2006-04-26 2007-11-08 Merck Sharp & Dohme Corp. Disubstituted aniline compounds
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
JP2009537529A (ja) 2006-05-18 2009-10-29 メルク エンド カムパニー インコーポレーテッド アリール縮合スピロ環化合物
US7981874B2 (en) 2006-07-20 2011-07-19 Merck Sharp & Dohme Corp. Phosphorus derivatives as histone deacetylase inhibitors
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
AU2008271170A1 (en) 2007-06-27 2009-01-08 Merck Sharp & Dohme Corp. Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
WO2010009196A1 (en) * 2008-07-15 2010-01-21 Temple University Of The Commonwealth System Of Higher Education Synthesis of bis-peptides oligomers comprising at least one n-substituted diketopiperazine as structural moiety
RU2455284C1 (ru) * 2011-03-15 2012-07-10 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" Способ получения 5-арил-2-метил-1,3-диоксо-2-азаспиро[5,5]ундекан-4-карбонитрилов и средство, проявляющее анальгетическую активность
WO2020246487A1 (ja) * 2019-06-04 2020-12-10 第一三共株式会社 ジスピロジケトピペラジン構造を有する化合物
RU2752079C1 (ru) * 2020-12-01 2021-07-22 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (Е)-(6-(2-гидроксифенил)-2-иминио-4,7,8-триоксо-1,3-дифенил-1,3,6-триазаспиро[4.4]нонан-9-илиден)(4-метоксифенил)метаноат, обладающий противомикробной активностью, и способ его получения

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ320963A (en) * 1995-09-29 1999-08-30 Lilly Co Eli Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
AU5803398A (en) * 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
JP2001508798A (ja) * 1997-01-21 2001-07-03 メルク エンド カンパニー インコーポレーテッド ケモカインレセプター活性のモジュレーターとしての３，３−二置換ピペリジン類
US6288083B1 (en) * 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CN1246321C (zh) * 1999-12-03 2006-03-22 小野药品工业株式会社 三氮杂螺[5,5]十一烷衍生物和含其作为活性成分的药物组合物
NZ528270A (en) * 2001-03-19 2005-10-28 Ono Pharmaceutical Co Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient

Also Published As

Publication number Publication date
CA2440264A1 (en) 2002-09-26
KR100714154B1 (ko) 2007-05-07
EP1378510A4 (en) 2004-09-29
HUP0400229A2 (hu) 2004-08-30
JPWO2002074770A1 (ja) 2004-07-08
CN1291988C (zh) 2006-12-27
ATE328884T1 (de) 2006-06-15
KR20040008142A (ko) 2004-01-28
US20040082584A1 (en) 2004-04-29
JP3558079B2 (ja) 2004-08-25
ES2266452T3 (es) 2007-03-01
NO20034148L (no) 2003-11-14
EP1619194A2 (en) 2006-01-25
IL157819A0 (en) 2004-03-28
US7262193B2 (en) 2007-08-28
EP1378510A1 (en) 2004-01-07
NO20034148D0 (no) 2003-09-17
DE60212110D1 (de) 2006-07-20
US20050215557A1 (en) 2005-09-29
RU2269528C2 (ru) 2006-02-10
RU2003128067A (ru) 2005-04-10
WO2002074770A1 (fr) 2002-09-26
TWI254047B (en) 2006-05-01
NZ528249A (en) 2005-03-24
MXPA03008529A (es) 2004-06-30
PL364427A1 (en) 2004-12-13
CN1518551A (zh) 2004-08-04
DE60212110T2 (de) 2006-11-09
AU2002238947B2 (en) 2007-10-18
US7053090B2 (en) 2006-05-30
EP1378510B1 (en) 2006-06-07
EP1619194A3 (en) 2006-06-07
PT1378510E (pt) 2006-09-29
DK1378510T3 (da) 2006-10-16
CZ20032531A3 (cs) 2004-01-14

Similar Documents

Publication Publication Date Title
BR0208167A (pt) Derivado triazaespiro[5.5]undecano e composição farmacêutica compreendendo o mesmo como um ingrediente ativo
NO20022609D0 (no) Triazaspiro[5,5]undekan-derivater og medikamenter inneholdende slike som den aktive bestanddel
UY27976A1 (es) Piperazinas heterocíclicas sustituídas para el tratamiento de la esquizofrenia
DE60322359D1 (de) Imidazopyridinderivate als kinaseinhibitoren
ATE384061T1 (de) Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren
BR0212829A (pt) Derivados de 1,8-naftiridina e seu uso para tratar diabetes e distúrbios relacionados
TW200510297A (en) Substituted n-aryl heterocycles, process for their preparation and their use as medicaments
ATE542818T1 (de) Imidazo- und triazolopyridinverbindungen und verfahren zu deren anwendung
PE20050089A1 (es) Derivados de azo [1,2-c] quinazolina condensados
BR0311605A (pt) Compostos de amida de ácido 3-aminotieno[2,3-b]piridina-2-carboxìlico substituìdo e processos para preparação e seus usos
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
HRP20050933A2 (en) Organic compounds
MX2009011089A (es) Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
BR0317658A (pt) Derivados de 1-piperidin-4-il-4-pirrolidin-3-il-piperazina substituìda e seu emprego como antagonistas de neuroquinina
ATE546452T1 (de) Pyrazolopyrrolderivate als proteinkinaseinhibitoren
BR0316108A (pt) Derivados de fenilalquil e piridilalquil piperazina e composição farmacêutica compreendendo os mesmos
HUP0401588A2 (hu) Rákellenes és proliferáció elleni hatású indeno[1,2-c]pirazol-4-on-származékok és ezeket tartalmazó gyógyszerkészítmények
DK1673354T3 (da) Arylindenopyridiner og arylindenopyrimidiner og deres anvendelse som adenosin-A2a-receptorantagonister
BR0314796A (pt) Piperazinas substituìdas heterocìclicas para o tratamento de esquizofrenia
NO20063562L (no) Fusjonerte heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
BRPI0416739A (pt) derivados de indano substituìdo heterocìclico e compostos afins para o tratamento de esquizofrenia
BR112022007680A2 (pt) Derivados de n-(heteroaril)quinazolin-2-amina como inibidores de lrrk2, composições farmacêuticas, e usos dos mesmos
HUP0102236A2 (hu) Kondenzált gyűrűs szubsztituenseket tartalmazó 2-aminopiridin-származékok, mint nitrogén-2-oxid-szintáz inhibitorok és ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
NO20081818L (no) Arylsulfonylkromaner som 5-HT6-inhibitorer - indolylmaleimidderivater som protein kinaseinhibitorer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.